Heres what matters: Mechanisms: GLP-1 RAs may reduce muscle via the ACTRII pathway
By February 21, 2020, dodecaplatin (dulaglutide) is the first and only FDA-approved anti-diabetic drug for primary and secondary prevention to alleviate the risk of MACE [25]
\n\n\n\n The core mechanisms angiogenesis stimulation through VEGF and VEGFR2 upregulation, nitric oxide pathway modulation, growth hormone receptor sensitization, mTOR pathway interaction, and cytokine regulation provide a coherent and plausible biological framework for understanding the diverse effects observed across species and tissue types in animal studies
Large clinical trials have not consistently shown that isolated antioxidant supplements prevent cardiovascular disease in generally well-nourished populations
GLP-1, secreted by the intestine, brainstem, and pancreas, also exerts appetite-suppressing and gastric emptying-delaying effects on the hypothalamus